News Releases

VANCOUVER, Feb. 5, 2015 /CNW/ – Neovasc Inc. (“Neovasc” or the “Company“) (NASDAQ: NVCN) (TSX: NVC) today announced that the final results from its COSIRA study assessing the efficacy and safety of the Neovasc Reducer™ for...

VANCOUVER, Feb. 3, 2015 /CNW/ – Neovasc Inc. (“Neovasc” or the “Company“) (NASDAQ: NVCN) (TSX: NVC) is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the...

VANCOUVER, Jan. 29, 2015 /CNW/ – Neovasc Inc. (“Neovasc” or the “Company“) (NASDAQ: NVCN) (TSX: NVC) is pleased to announce that due to market interest, it has increased the size of its previously announced underwritten public...

VANCOUVER, Jan. 26, 2015 /CNW/ – Neovasc Inc. (“Neovasc” or the “Company“) (NASDAQ: NVCN) (TSX: NVC) today announced that it has commenced an underwritten public offering in the United States of 8,000,000 common shares of the...

VANCOUVER, Jan. 13, 2015 /CNW/ – Neovasc Inc. (“Neovasc” or the “Company“) (NASDAQ: NVCN) (TSX: NVC) today announced it will visit the Nasdaq MarketSite in Times Square in celebration of its Nasdaq listing. Neovasc is focused on...

VANCOUVER, Dec. 1, 2014 /CNW/ – Neovasc Inc. (“Neovasc” or the “Company“) (NASDAQ: NVCN) (TSX: NVC) today announced that the first patient has been enrolled in the European arm of its TIARA-I Early Feasibility Trial, a...

–Tiara receives conditional approval from FDA for Early Feasibility Study– –Reducer Live Case completed successfully at TCT 2014–